Avere goes public via reverse merger, pays $120M for Hansoh drug
Avere goes public via reverse merger, pays $120M for Hansoh drug
Avere Therapeutics
NASDAQ: AVERE ~$0.3B (post-merger) MCAP
Avere Therapeutics is a clinical-stage immunology company developing drugs for autoimmune and inflammatory diseases. The company was formed from the former Akero Therapeutics team and entered the public markets via a reverse merger, also acquiring rights to a Hansoh Pharmaceutical drug for $120M.
Company Info
Sector:Immunology / Inflammation
Headquarters:South San Francisco, California, USA
Founded:2026
Website:www.avere-tx.com/
Upcoming Milestones & Key Dates
2026-Q4
Strategic
Pipeline expansion announcements post reverse merger
Clinical Development Pipeline
Hansoh-licensed compound
Target: UndisclosedRecent News
Leadership Team
TBD
CEO
TBD
Chief Scientific Officer
TBD
Chief Medical Officer
Careers & Job Openings